RT @DrPetryna: @RheumNow #acr20 abs0665 claim based database stdy of pegloticase/immunomodulation coadministration trend
Tweet Content
@RheumNow #acr20 abs0665 claim based database stdy of pegloticase/immunomodulation coadministration trends: use of co-immunomodulation ⬆️ from 1.2%-3.9% 2015- 2018 to 15.0% in 2019. 86%start immunomodulator within 30 days of first peg infusion. MTX most commonly used
Show on Archive Page
On
Display in Search Results
On